Authors

    Language

    English

    Publication Date

    6-1-2020

    Journal

    The Journal Of Clinical And Aesthetic Dermatology

    PMID

    32884622

    PMCID

    PMC7442303

    PubMedCentral® Posted Date

    6-1-2020

    PubMedCentral® Full Text Version

    Post-print

    Abstract

    Isotretinoin has unmatched efficacy in the treatment of acne. However, because isotretinoin is a teratogen that can cause profound birth defects, the iPLEDGE program regulates the drug's distribution in the United States. To minimize fetal exposure to isotretinoin, the program requires that female patients capable of becoming pregnant use two forms of contraception or commit to abstinence while using this therapy. This manuscript argues that iPLEDGE should be revised to remove abstinence as an acceptable contraceptive option in the face of evidence that disputes its efficacy. All patients, regardless of reported sexual activity, should be required to use data-proven contraception. Potential benefits of the proposed change (iPLEDGE-R) include reducing the number of isotretinoin pregnancies, increasing patient privacy protection, and standardizing patient care. Further investigation needs to guide additional strategies to achieve the program's public health goal; however, the ethical and pragmatic advantages of iPLEDGE-R merit consideration.

    Keywords

    Isotretinoin, Accutane, acne, iPLEDGE, REMS, pregnancy, teratogen, abstinence, contraception, birth control, risk management, FDA

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.